Literature DB >> 17602969

Progress in basic inflammatory bowel disease research.

Subra Kugathasan1, Claudio Fiocchi.   

Abstract

A modern approach to inflammatory bowel disease (IBD) research has been under way for little over one-half century, but only during the last two decades has progress accelerated and finally generated tangible results that have been translated into practical and better therapeutic strategies. The areas where progress has been more evident are those currently believed to be the key components of IBD pathogenesis, and include the environment, genetics, enteric microbiology, and immune reactivity. Progress in these different areas has been somewhat uneven, yielding a better understanding of the mechanisms behind gut inflammation and tissue injury rather than of specific etiological agents or predisposing factors. However, with the rapidly increasing utilization of novel methodological approaches like genetics, genomics, proteomics, and pharmacogenomics, it is reasonable to anticipate that the etiopathogenesis of IBD will be unveiled in the next couple of decades and more definitive, perhaps disease-modifying, approaches will be uncovered and implemented.

Entities:  

Mesh:

Year:  2007        PMID: 17602969     DOI: 10.1053/j.sempedsurg.2007.04.002

Source DB:  PubMed          Journal:  Semin Pediatr Surg        ISSN: 1055-8586            Impact factor:   2.754


  13 in total

Review 1.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

Review 2.  Inflammatory bowel disease: pathogenesis.

Authors:  Yi-Zhen Zhang; Yong-Yu Li
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  T300A polymorphism of ATG16L1 and susceptibility to inflammatory bowel diseases: a meta-analysis.

Authors:  Jia-Fei Cheng; Yue-Ji Ning; Wei Zhang; Zong-Hai Lu; Lin Lin
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

4.  State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

5.  miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn's disease.

Authors:  Xiuqin Cheng; Xiaofei Zhang; Jiewen Su; Yingdi Zhang; Weimei Zhou; Jun Zhou; Cheng Wang; Hongwei Liang; Xi Chen; Ruihua Shi; Ke Zen; Chen-Yu Zhang; Hongjie Zhang
Journal:  Sci Rep       Date:  2015-05-22       Impact factor: 4.379

6.  Shen-Ling-Bai-Zhu-San for ulcerative colitis: Protocol for a systematic review and meta-analysis.

Authors:  Long Yang; Yuanyuan Song; Pei Jin; Yueyang Liu; Yue Wang; Huixia Qiao; Yahui Huang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

Review 7.  Intestinal Microbiota in Early Life and Its Implications on Childhood Health.

Authors:  Lu Zhuang; Haihua Chen; Sheng Zhang; Jiahui Zhuang; Qiuping Li; Zhichun Feng
Journal:  Genomics Proteomics Bioinformatics       Date:  2019-04-12       Impact factor: 7.691

Review 8.  The role of diet in the prevention and treatment of Inflammatory Bowel Diseases.

Authors:  Rosa Reddavide; Ornella Rotolo; Maria Gabriella Caruso; Elisa Stasi; Maria Notarnicola; Chiara Miraglia; Antonio Nouvenne; Tiziana Meschi; Gian Luigi De' Angelis; Francesco Di Mario; Gioacchino Leandro
Journal:  Acta Biomed       Date:  2018-12-17

Review 9.  Inflammatory bowel disease pathobiology: the role of the interferon signature.

Authors:  Nicolaos-Panagiotis Andreou; Evangelia Legaki; Maria Gazouli
Journal:  Ann Gastroenterol       Date:  2020-02-12

Review 10.  siRNA Targeting and Treatment of Gastrointestinal Diseases.

Authors:  Rachel Chevalier
Journal:  Clin Transl Sci       Date:  2019-08-05       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.